Literature DB >> 2139449

Atrial natriuretic peptide in Cushing's disease.

G Opocher1, S Rocco, G Carpenè, F Pedini, M Scarante, R Milani, M Boscaro, F Mantero.   

Abstract

Atrial Natriuretic Peptide (ANF), is secreted by atrial myocytes in response to atrial stretch. Its plasma levels have been found elevated in conditions leading to salt and fluid repletion and consequent atrial distention. Recently, it has been demonstrated that dexamethasone can enhance ANF secretion, by acting on ANF gene expression and mRNA synthesis. High plasma levels of ANF have been observed in normal man after administration of cortisol and ACTH. In the case of glucocorticoid excess, as in Cushing's disease, limited and conflicting data are available. Therefore, we measured ANF basal values and ANF response to postural changes and volume expansion in eight patients with Cushing's disease. In our patients ANF values were higher than normals. ANF responded to volume expansion, 47.8 +/- 5.1 pg/ml before sodium load and 69.9 +/- 7.0 pg/ml after sodium load, and changed minimally after postural manoeuvres, 47.3 +/- 3.2 pg/ml supine and 41.7 +/- 5.1 pg/ml upright. These data indicate that ANF secretion is enhanced in Cushing's disease, and its regulation is partially altered. Since in this condition hypervolemia has not been certainly demonstrated, a direct relationship between elevated ANF and glucocorticoid excess could be suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139449     DOI: 10.1007/BF03349522

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man.

Authors:  J M Connell; J A Whitworth; D L Davies; A F Lever; A M Richards; R Fraser
Journal:  J Hypertens       Date:  1987-08       Impact factor: 4.844

2.  Atrial natriuretic polypeptide inhibits cortisol secretion as well as aldosterone secretion in vitro from human adrenal tissue.

Authors:  M Naruse; K Obana; K Naruse; H Yamaguchi; H Demura; T Inagami; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1987-01       Impact factor: 5.958

3.  Glucocorticoid and mineralocorticoid stimulation of atrial natriuretic peptide release in man.

Authors:  P Weidmann; D R Matter; E E Matter; M P Gnädinger; D E Uehlinger; S Shaw; C Hess
Journal:  J Clin Endocrinol Metab       Date:  1988-06       Impact factor: 5.958

4.  Plasma levels of atrial natriuretic hormone in Cushing's syndrome.

Authors:  T Yamaji; M Ishibashi; A Yamada; F Takaku; A Itabashi; S Katayama; J Ishii; M Takami; T Fukushima
Journal:  J Clin Endocrinol Metab       Date:  1988-08       Impact factor: 5.958

Review 5.  Human atrial natriuretic peptide.

Authors:  E A Espiner; M G Nicholls
Journal:  Clin Endocrinol (Oxf)       Date:  1987-05       Impact factor: 3.478

6.  Cardiac glucocorticoid receptors: the binding of tritiated dexamethasone in rat and dog heart.

Authors:  J W Funder; D Duval; P Meyer
Journal:  Endocrinology       Date:  1973-12       Impact factor: 4.736

7.  Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.

Authors:  T Saruta; H Suzuki; M Handa; Y Igarashi; K Kondo; S Senba
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

8.  Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man.

Authors:  P Weidmann; B Hellmueller; D E Uehlinger; R E Lang; M P Gnaedinger; L Hasler; S Shaw; C Bachmann
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

9.  Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone.

Authors:  M L Day; D Schwartz; R C Wiegand; P T Stockman; S R Brunnert; H E Tolunay; M G Currie; D G Standaert; P Needleman
Journal:  Hypertension       Date:  1987-05       Impact factor: 10.190

10.  Atrial natriuretic peptide mRNA is regulated by glucocorticoids in vivo.

Authors:  D G Gardner; S Hane; D Trachewsky; D Schenk; J D Baxter
Journal:  Biochem Biophys Res Commun       Date:  1986-09-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.